Jaipur, April 22, 2026: The Commissionerate of Food Safety and Drug Control, Rajasthan, has banned seven medicines after declaring them Not of Standard Quality following rigorous laboratory testing conducted between April 1 and April 15, 2026. The regulatory crackdown, one of the most significant drug quality enforcement actions in the state this year, has prompted immediate withdrawal orders across all government and private healthcare facilities in Rajasthan.

Regulatory Action and Withdrawal Orders

Drug Controller Ajay Phatak has directed all Drug Control Officers across Rajasthan to immediately pull the identified batches from circulation and initiate strict legal proceedings under the Drugs and Cosmetics Act, 1940. Instructions have been issued to all government and private hospitals, medical colleges, pharmacies, and distributors to halt the sale, distribution, and use of the flagged medicines without delay.

Phatak further directed that additional batches from the same manufacturers be subjected to comprehensive quality testing to prevent further risk to public health. The department warned that any violation of these directives will invite stringent legal action under applicable regulatory frameworks.

The Seven Banned Medicines — Full List

Commissioner Dr. T. Shubhamangala confirmed that the latest testing cycle exposed multiple pharmaceutical products failing to meet prescribed quality parameters, raising critical concerns over their efficacy, safety, and therapeutic reliability.

1. Cefixime Oral Suspension IP (LORAXIM Dry Syrup 12g/30 ml) — Batch LXS3-49, Expiry October 2026, manufactured by M/s Lark Laboratories (India) Ltd., Bhiwadi, Alwar. Failed assay test; active ingredient content did not conform to prescribed standards.

2. Albendazole Tablets IP — Batch PG124427, Expiry June 2027, manufactured by M/s Affy Parenterals, Baddi, Solan, Himachal Pradesh. Failed dissolution test, indicating inadequate release of the active ingredient in the body.

3. Ambroxol Hydrochloride, Levosalbutamol and Guaiphenesin Drops (Istocuf-LS) — Batch GLF0712B, Expiry June 2027, manufactured by M/s Digital Vision, Kala Amb, Sirmaur, Himachal Pradesh. Assay content found non-compliant with required standards.

4. Methylprednisolone Tablets IP 4 mg (Methyloactive-4) — Batch 252005, Expiry June 2027, manufactured by M/s United Bioceuticals Pvt. Ltd., Haridwar. Failed both assay and dissolution tests, indicating multiple quality deficiencies.

5. Dextromethorphan HBr and Chlorpheniramine Maleate Syrup (Okuff-DX) — Batch TLLM-188, Expiry November 2026, manufactured by M/s Taksa Lifesciences Pvt. Ltd., Derabassi, Mohali. Chlorpheniramine Maleate content found below permissible limits.

6. Cefuroxime Axetil Tablets IP (EXTENSIVE-500) — Batch VT252942, Expiry February 2028, manufactured by M/s VADSP Pharmaceuticals, Baddi. Failed assay testing.

7. Ciprofloxacin Tablets IP 500 mg — Batch GT50135, Expiry April 2028, manufactured by M/s Omega Pharma, Roorkee, Haridwar. Failed both assay and dissolution parameters.

Why This Matters — Public Health at Stake

Sub-standard medicines pose a direct and serious threat to patient safety. When a drug fails an assay test, it means the active ingredient is either absent, insufficient, or in excess — rendering the medicine therapeutically ineffective or potentially harmful. A failed dissolution test means the drug does not break down properly in the body, preventing absorption and making treatment futile.

The banned drugs span critical therapeutic categories — antibiotics (Cefixime, Cefuroxime, Ciprofloxacin), anti-parasitic (Albendazole), corticosteroids (Methylprednisolone), respiratory medicines (Ambroxol), and cough syrups — meaning patients being treated for infections, respiratory conditions, and inflammatory diseases may have been receiving ineffective treatment.

This is particularly alarming given that antibiotic resistance is already a growing public health crisis in India. Patients consuming sub-potent antibiotics not only fail to recover but inadvertently contribute to drug-resistant bacterial strains, a threat that extends far beyond individual health.

Department Surveillance Mechanism

Dr. T. Shubhamangala emphasized that the department conducts regular inspections, sampling, and quality surveillance to ensure only safe, effective, and compliant medicines reach the public and healthcare institutions. The April 1–15 testing cycle is part of a continuous state-wide drug quality monitoring program.

Notably, the flagged manufacturers are spread across multiple states — Rajasthan, Himachal Pradesh, and Uttarakhand — highlighting that sub-standard drug manufacturing is not confined to a single geography and underscores the need for coordinated national-level enforcement. Baddi in Himachal Pradesh, which appears twice in this list, is one of India's largest pharmaceutical manufacturing hubs and has previously attracted regulatory scrutiny from the Central Drugs Standard Control Organisation (CDSCO).

Broader Implications and What Comes Next

This crackdown comes amid growing national concerns over the quality of medicines manufactured in India, particularly following high-profile international incidents involving Indian-made pharmaceutical products in recent years. India's drug regulatory ecosystem has faced criticism for being under-resourced relative to the scale of its pharmaceutical industry.

The Rajasthan Food Safety and Drug Control department has signaled that enforcement will intensify, with additional batch testing from the same manufacturers already underway. Citizens and healthcare providers are urged to verify medicine batches before use and report any suspicious products to the nearest Drug Control Officer.

As India's pharmaceutical sector faces mounting scrutiny both domestically and globally, actions like this one from Rajasthan set a critical precedent for proactive state-level enforcement that could pressure other states to strengthen their own drug quality surveillance systems.